Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development

Eric So and Paul Glavine, Co-founders of Helus Pharma

“Helus Pharma has reached an important stage in its development, and we believe the Company is well positioned to advance its programs through the next phase of growth. We have complete confidence in our recently appointed CEO, Michael Halstead, our Board of Directors and the rest of our experienced leadership and scientific team, and in their ability to execute on the Company’s strategic priorities and advance its lead programs through commercialization. We believe Helus Pharma is at the right point in its growth trajectory for this transition, and we look forward to continuing to support the Company’s execution and growth in our capacity as members of the Board of Directors.”

Mark Lawson, Independent Chair of the Board of Directors, Helus Pharma

“I am honored by the Board’s confidence in appointing me as Chair of the Board and have great confidence in the Company’s leadership, pipeline and future. We have an experienced leadership team and I look forward to working with the Board and management in executing against the upcoming HLP003 and HLP004 clinical, regulatory, and commercial milestones”

Michael Halstead, Chief Executive Officer of Helus Pharma

“I want to thank Eric and Paul for the confidence they have shown in me and for their continued support of the Company and the broader leadership team. Their contributions have established a strong foundation for the Company, its programs and its mission to make important new mental health treatments available to people in need. As we continue to execute against upcoming milestones, their continued involvement at the Board level will be invaluable.”